CorneaGen
  • SURGEON PORTAL
  • Contact Us
  • CORNEAL TISSUE
    • Tissue Overview
    • Tissue Services
      • DSAEK
      • DMEK
      • Geuder Pre-Loaded Glass Cannula
      • Ampho B
      • PKP
      • ALK
      • BrightMEM
      • FLAK
      • Non-Sterile Sclera
    • Tissue Reimbursement
    • Adverse Reaction Reporting
    • Regulatory Information
    • Request Tissue
  • Sterile Tissue
    • CTAK
    • VisionGraft
      • Glaucoma
      • Cornea
    • Sclera
    • Reimbursement
      • VisionGraft Reimbursement
    • Adverse Reaction Reporting
    • Regulatory Information
  • CTAK
    • CTAK Overview
    • CTAK Reimbursement
  • Products
    • Products Overview
    • EndoSerter-PL
    • EndoSerter
    • Cannula
    • Geuder Pre-Loaded Glass Cannula
    • DescePro System
    • Donor Punch
    • Recipient Trephine
    • Intacs
  • Education
    • Educational Videos
    • Wet Labs
    • Fellows Program
  • About Us
    • Our People
    • Our Partners
    • Our Locations
    • Reimbursement
    • Gift of Sight
    • News & Events
    • Core Commitments
    • Innovation
    • Careers
Request Tissue Contact Us

David Hardten on CTAK

October 16, 2023

Keratoconus is a very frustrating disease with visual disability often requiring a corneal transplant when vision degrades to where glasses or contacts don’t work well. CTAK corneal tissue addition provides a great option for those patients with quick recovery, improved vision without the long recovery or risk of a corneal transplant. We’ve been very happy with the results.

Recent Articles

  • Bernie’s Quarterly Update – November 2024

    Bernie’s Quarterly Update – November 2024

    A message from Bernie Iliakis, President & CEO of CorneaGen...

    READ MORE
  • Bernie’s Quarterly Update – July 2024

    Bernie’s Quarterly Update – July 2024

    A message from Bernie Iliakis, President & CEO of CorneaGen...

    READ MORE
  • CorneaGen Launches CTAK, an Innovation for Improved Patient Outcomes

    CorneaGen Launches CTAK, an Innovation for Improved Patient Outcomes

    CorneaGen Launches CTAK, an Innovation for Improved Patient Outcomes Advanced...

    READ MORE
  • CTAK Update from ASCRS 2024

    CTAK Update from ASCRS 2024

    Hear from Dr. Steven Greenstein and Dr. Peter Hersh from...

    READ MORE
Navigation
  • Corneal Tissue
  • Products
  • Innovation
  • Education
  • About Us
  • Request Tissue
Helpful Information
  • Reimbursement assistance
  • Adverse reaction reporting
  • KAMRA Support
  • Careers
Legal
  • Privacy Policy
  • Terms and conditions
  • Regulatory Information
Connect
  • Contact Us
CorneaGen

©2025 CorneaGen

CorneaGen